Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Inventiva Full Year 2025 Earnings Call - NATiV3 Readout Slotted for Q4 2026; Company Pivots Solely to Lanifibranor
Inventiva closed 2025 with NATiV3 enrollment complete and a sharpened corporate focus: every resource is now directed at getting lanifibranor to market for MASH. Management updated the pivotal topline...
- NATiV3 enrollment completed April 2025; main cohort exceeded 1,000 patients (reported ~1,009) and an exploratory cohort of ~410 patients (includes compensated F1-F4, roughly 75 F4).
- Top-line readout timing updated to Q4 2026, presented as the company’s next major inflection point for regulatory and commercial plans.
- Trial powered to over 90% for the composite primary endpoint of fibrosis improvement plus MASH resolution, with sample size designed to tolerate up to 30% dropouts; company reports dropouts well below that covenant threshold.
- +12 more takeaways
Bitfarms FY2025 Earnings Call - Rebrand to Keel Infrastructure and Full Pivot to 2.2 GW North American HPC/AI Pipeline
Bitfarms used the FY2025 call to draw a hard line under Bitcoin mining and present itself as a new company: Keel Infrastructure. Management confirmed U.S. re-domiciliation and an imminent rebrand, a s...
- Company will re-domicile to the U.S. and rebrand as Keel Infrastructure, with the change expected to complete April 1 and listing under ticker Keel two business days after the transaction.
- Management declared a full strategic pivot from Bitcoin mining to North American HPC and AI infrastructure, saying the legacy Bitcoin business will be left behind by 2027.
- Keel reports a roughly 2.2 GW pipeline of secured and expandable capacity across Pennsylvania, Washington State, and Quebec, with a stated focus on powered-shell and colocation product types.
- +12 more takeaways
NextPlat Corporation Year-End 2025 Earnings Call - Early margin gains and national healthcare expansion via HealthWarehouse
NextPlat spent 2025 digging itself out, and management says the work is starting to show. Revenue fell to about $54 million, but cost cuts, a shift toward higher margin 340B and medication fulfillment...
- Company completed a reverse stock split to maintain Nasdaq listing; management frames it as necessary and says insiders remain large shareholders.
- Total revenue for 2025 was approximately $54 million, down 18% from $66 million in 2024.
- Healthcare operations generated about $40 million in 2025, roughly 73% of consolidated revenue, down from approximately $52 million in 2024.
- +12 more takeaways
J.Jill Q4 2025 Earnings Call - Investing to expand customer file amid tariff headwinds and promotional pressure
J.Jill calls 2025 the start of a deliberate strategic evolution, trading near-term profitability for investments aimed at broadening its customer file. Q4 beat the companys updated guidance but showed...
- Q4 2025 total sales $138.4 million, down 3.1% year over year; total company comparable sales down 4.8%, driven by retail weakness.
- Q4 gross profit $87.3 million, gross margin 63.1%, down 320 basis points versus Q4 2024, impacted by approximately $4.5 million of net tariff costs and deeper discounting.
- Q4 adjusted EBITDA $7.2 million versus $14.5 million in Q4 2024; adjusted EPS loss of $0.02 versus $0.32 prior year.
- +12 more takeaways
AIRO Group Holdings, Inc. Q4 2025 Earnings Call - Drone-led momentum, $150M backlog and U.S. manufacturing ramp set stage for 15%-25% 2026 growth
AIRO closed 2025 as a drone company first, with drones accounting for roughly 87% of revenue, U.S. manufacturing coming online, and a roughly $150 million drone backlog that management says has strong...
- 2025 revenue was $90.9 million, with Q4 revenue of $48.3 million, up from $39.7 million in Q4 2024.
- Drones drove the business, representing approximately 87% of total 2025 revenue; the drone segment remains the primary growth engine.
- Drone segment backlog was reported at about $150 million as of March 31, 2026, translated to USD at market close March 27, 2026; management says it has strong visibility on a meaningful portion converting within 12 months.
- +12 more takeaways
Jiayin Group Fourth Quarter 2025 Earnings Call - Compliance-first pivot, short-term shrinkage for longer-term quality growth
Jiayin told investors it chose defense over offense in the new regulatory era, tightening borrower intake and reworking risk controls even as volumes and near-term margins fell. Management highlighted...
- Management adopted a compliance-first strategy after new regulation, deliberately tightening borrower acquisition and underwriting to protect asset quality.
- Full-year 2025 loan facilitation volume was reported at RMB 129 billion, roughly +28% year-on-year according to management remarks.
- Q4 2025 facilitation volume declined to RMB 24.2 billion, down 12.6% year-on-year; Q4 net revenue was RMB 1,090.2 million, down 22.4% year-on-year.
- +12 more takeaways
DiaMedica Therapeutics Full Year 2025 Earnings Call - Preeclampsia signal: BP reduction, no placental crossing, Phase II expansion
DiaMedica reported 2025 progress driven by DM199, a recombinant KLK1, with the clearest near-term readout coming from investigator-sponsored preeclampsia work. Interim Part 1-A data showed dose-depend...
- Interim Part 1-A preeclampsia data showed dose-dependent, statistically significant reductions in systolic and diastolic blood pressure in hypertensive women expected to deliver within 72 hours.
- DM199 significantly reduced uterine artery pulsatility index, a Doppler measure that suggests improved utero-placental perfusion and lower vascular resistance.
- Safety signal notable: DM199 did not cross the placental barrier in the patients studied, and no passage into breast milk was detected, strengthening maternal-only exposure profile.
- +11 more takeaways
IZEA Q4 2025 Earnings Call - Strategic Pivot Delivers Break-even and $50.9M Cash
IZEA says 2025 was a reset year and the numbers back it up. Annual revenue fell to $31.2 million, down 13% as management deliberately off-boarded lower-margin SMBs and exited international markets, bu...
- Company executed a deliberate strategic pivot in 2025, prioritizing enterprise accounts and off-boarding lower-margin SMBs and international operations.
- Annual revenue was $31.2 million in 2025, down 13% year-over-year, reflecting the intentional repositioning and macro headwinds.
- Q4 2025 revenue was $6.1 million, a 45% decline year-over-year, with management saying more than half the decline came from strategic client rationalization.
- +11 more takeaways
RenovoRx Q4 2025 Earnings Call - Commercial ramp ahead as TIGeR-PaC nears enrollment
RenovoRx closed 2025 as a fledgling commercial company, generating $1.1 million for the year and $238,000 in Q4 while converting early clinical users into paying customers. Management says the busines...
- Q4 2025 revenue was $238,000, full-year 2025 revenue totaled $1.1 million, reflecting an early, concentrated commercial footprint.
- RenovoRx reports a very high gross margin in Q4, 88% gross margin on product revenue for the quarter.
- As of February 27, 2026, 12 U.S. cancer centers are actively using RenovoCath, and another 21 centers are evaluating or preparing for activation, a near-term pipeline of 33 centers.
- +12 more takeaways
Innventure Q4 2025 Earnings Call - Platform crosses from potential to performance as Accelsius books $50M+ and targets cash flow breakeven in 2026
This call was a stop-the-presses moment for Innventure. Management argues the business has moved from thesis to proof, with three operating companies simultaneously hitting commercial inflection point...
- Management frames Q4 2025 and Q1 2026 as a structural inflection, claiming the platform has moved from potential to demonstrable performance across multiple operating companies.
- Accelsius booked over $50 million of contracted backlog in Q1 2026, described as production-volume orders rather than pilots, providing leading visibility into 2026 revenue growth.
- Innventure expects Accelsius to exit 2026 cash flow breakeven, implying a December 2026 annual revenue run rate of roughly $100 million, with revenue skewed to the back half of the year due to supply chain timing.
- +17 more takeaways